Oryzon Genomics - Favorable safety reported in PORTICO Phase II
Oryzon presented a positive update on vafidemstat’s ongoing Phase IIb PORTICO trial in borderline personality disorder (BPD) at the ECNP Congress....
301 Views
Oryzon Genomics - Grants provide confidence and expand portfolio
Oryzon has announced that it has received two separate grants from the Spanish State Research Agency and the Ministry of Science and Innovation to...
369 Views
Oryzon Genomics - H123 progress and results came in as expected
Oryzon’s H123 results highlight the continued progress of its lead clinical-stage assets, including positive aggregate safety data from the Phase...
345 Views
Oryzon Genomics - Positive safety data for vafidemstat in PORTICO
Oryzon has announced positive aggregate safety data for vafidemstat, which is being evaluated in the ongoing PORTICO trial as a potential treatment...
339 Views
Oryzon Genomics - Advancing on multiple clinical fronts in Q1
Oryzon has reported Q123 results highlighting its near-term strategic priorities, including a favourable interim analysis of its lead asset study,...
309 Views